arrow
M

Michael S. Khodadoust

University of Colorado Anschutz
H指数:33
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders

Merkel细胞多瘤病毒阳性T细胞淋巴增生性疾病的临床病理及分子特征

2026-05-010
PRE
Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine

胃肠道CAR T细胞淋巴瘤的长期随访:归巢、克隆性增殖及对环孢素的治疗反应

Blood
IF23.1
2025-11-270
PRE
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
2024-11-150
OA
Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival

循环肿瘤DNA (ctDNA) 实现了急性髓系白血病 (AML) 中更优越且通用的可测量微小残留病 (MRD) 监测,对无复发生存期和总生存期具有高度预测性。

BLOOD
IF23.1
2024-11-051
PRE
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplantin Mcosis Fungoides and Sezary Syndrome
2024-11-010
PRE
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Duvelisib联合romidepsin治疗复发/难治性T细胞淋巴瘤: 1b/2a期试验

2024-06-171
PRE
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis

通过连续肿瘤采样和单细胞分析对淋巴瘤进行治疗性疫苗接种的临床试验

2023-12-291
OAAI
Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study
2023-09-010
PRE
Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning
2023-09-010
PRE